1. Measurement of left ventricular function as an endpoint in trials of thrombolytic therapy. Coronary Artery non-Q-wave infarction, and least for those with Dis 1990; 1: 13-22. non-infarction. Those who died lost the greatest;Sheehan, F.H.
2. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a number of quality adjusted days, while those who comparison between intravenous tissue plasminogen lived lost more quality adjusted days if infarction activator and intravenous streptokinase;Chesebro, J.H.; Knatterud, G.; Roberts, R.;Circulation,1987
3. Discrepancies between the effects of a satisfactory gauge of the quality and quantity of coronary reperfusion on survival and left ventricular life. function;de Werf F, Van;Lancet,1989
4. Kind P. A scale of valuations of states of illness: is there a social consensus?;Rosser, R.;Int J Epidemiol,1978
5. The measurement of hospital very sensitive to small differences in the quality of output;Rosser, R.M.; Watts, V.C.;Int Epidemiol,1972